Who are Arificial Tear's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Non-Lipid Artificial Tear, Refresh Endura, Systane PRO, Advanced Eye Relief, Hyaluronic acid 0.05% & Ectoine 2.0%, Rohto (r) Hydra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/arificial-tear.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Arificial Tear — Competitive Intelligence Brief

Arificial Tear (Arificial Tear) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic lubricant. Area: Ophthalmology.

marketed Ophthalmic lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Arificial Tear (Arificial Tear) — Massachusetts Eye and Ear Infirmary. Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Arificial Tear TARGET	Arificial Tear	Massachusetts Eye and Ear Infirmary	marketed	Ophthalmic lubricant
Non-Lipid Artificial Tear	Non-Lipid Artificial Tear	University of Seville	marketed	Artificial tear / Ophthalmic lubricant
Refresh Endura	Refresh Endura	Federal University of São Paulo	marketed	Ophthalmic lubricant / Artificial tear
Systane PRO	Systane PRO	Scripps Poway Eyecare and Optometry	marketed	Ophthalmic lubricant / artificial tear
Advanced Eye Relief	Advanced Eye Relief	Galderma R&D	marketed	Ophthalmic lubricant and decongestant
Hyaluronic acid 0.05% & Ectoine 2.0%	Hyaluronic acid 0.05% & Ectoine 2.0%	Michael Marchand, MD	marketed	Ophthalmic lubricant and protectant
Rohto (r) Hydra	Rohto (r) Hydra	ORA, Inc.	marketed	Ophthalmic lubricant / Artificial tear

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic lubricant class)

Allergan · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Massachusetts Eye and Ear Infirmary · 1 drug in this class
National University of Malaysia · 1 drug in this class
Nguyen Viet Giap · 1 drug in this class
Ophthalmic Consultants of Long Island · 1 drug in this class
Tianjin Medical University Eye Hospital · 1 drug in this class
Universidad Nacional de Colombia · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Arificial Tear — Competitive Intelligence Brief. https://druglandscape.com/ci/arificial-tear. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab